CClinicalTrials.gg
Status unknownNCT03720249Updated May 14, 2019

Effects of Supplementation of Compound Nutrients on Plasma Homocysteine in Chinese Adults With Hyperhomocysteinemia

An interventional study of supplementation of compound nutrients and placebo control in Hyperhomocysteinemia, sponsored by Huilian Zhu. Status unknown at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-05-14.

Sponsored by Huilian Zhu · Not applicable, Interventional, and Basic science

The sponsor has not verified this record recently (last verified May 2019), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to determine whether supplementation of compound nutrients,including folic acid, vitamin B6, vitamin B12, betaine and zinc, will decrease the level of plasma homocysteine in Chinese adults with hyperhomocysteinemia.

02

Conditions studied

  • Hyperhomocysteinemia

Browse trials for

03

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. People aged 18-65 years.
  2. The level of plasma homocysteine is 15-100μmol/L.
  3. Free from products which could decrease plasma homocysteine for at least one month.
  4. Willing to participate in the study, consume the test product and perform all measurements.

Exclusion criteria

Exclusion Criteria:

  1. pregnant or lactating women.
  2. severe diseases need to control.
  3. people who unconsciousness and can not complete questionnaire.
  4. long-term regular use of vitamin or mineral supplements.
04

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    supplementation of compound nutrients

    Betaine、(6S)-5-methyltetrahydrofolic acid、vitamin B6、vitamin B12 and zinc are provided as a 800mg tablet. And the tablet is orally taken once a day, four tablets at a time for 12 weeks.

    Dietary Supplement: supplementation of compound nutrients

  • Placebo comparator
    placebo control

    The placebo is an excipient and the color, flavor, shape, taste and weight are same with the tablet of betaine、(6S)-5-methyltetrahydrofolic acid、vitamin B6、vitamin B12 and zinc supplement.

    Dietary Supplement: placebo control

Interventions

  • Dietary supplementsupplementation of compound nutrients

    Betaine、 (6S)-5-methyltetrahydrofolic acid、vitamin B6、vitamin B12 and zinc per day orally for 12 weeks.

    Also known as: Betaine、 (6S)-5-methyltetrahydrofolic acid、vitamin B6、vitamin B12 and zinc supplement

  • Dietary supplementplacebo control

    The placebo is an excipient and the color, flavor, shape, taste and weight are same with the tablet of supplement.

05

What researchers measure

Primary outcomes

  1. levels of homocysteine

    At baseline, 4 weeks and 12 weeks, blood samples will be drawn and levels of homocysteine will be tested in two groups.

    Time frame: 12 weeks

Secondary outcomes

  1. levels of 5-methyltetrahydrofolic acid, vitamin B6, vitamin B12 and betaine

    At baseline, 4 weeks and 12 weeks, blood samples will be drawn and levels of 5-methyltetrahydrofolic acid, vitamin B6, vitamin B12 and betaine will be tested in two groups.

    Time frame: 12 weeks

  2. levels of s-adenosyl-methionine and s-adenosyl-homocysteine

    At baseline, 4 weeks and 12 weeks, blood samples will be drawn and levels of s-adenosyl-methionine (SAM) and s-adenosyl-homocysteine (SAH) will be tested in two groups.

    Time frame: 12 weeks

  3. anthropomorphic measurements and blood biochemical markers

    Anthropomorphic measurements such as height, weight, waist circumference, hip circumference, vascular endothelial function, cardiopulmonary function, body composition and so on, and blood biochemical markers such as overnight fasting serum total cholesterol (TC), triglyceride (TG), LDL cholesterol (LDLc), HDL cholesterol (HDLc), fasting blood glucose and so on will be measured.

    Time frame: 12 weeks

06

Study locations

1 site
  • SunYat-sen University
    Guangzhou, Guangdong 510080, China
07

Registry details

Key details

Study ID
NCT03720249
Lead sponsor
Huilian Zhu
Responsible party
Huilian Zhu (professor, Sun Yat-sen University) — Sponsor-investigator
First posted
Oct 25, 2018
Start date
May 20, 2019 (estimated)
Primary completion
Dec 31, 2022 (estimated)
Completion
Dec 31, 2022 (estimated)
Last update
May 14, 2019

Study contacts

Huilian Zhu, professor
Contact
zhuhl@mail.sysu.edu.cn
+86 20 87331811
Huilian Zhu, professor
study chair · Sun Yat-sen University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion